Affiliation:
1. Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Abstract
ABSTRACT
The laboratory diagnosis of antiviral resistance is a quickly changing field due to new drug availability, the sunsetting of older drugs, the development of novel technologies, rapid viral evolution, and the financial/logistic pressures of the clinical laboratory. This mini-review summarizes the current state of clinically available antiviral resistance testing in the United States in 2024, covering the most commonly used test methods, mechanisms, and clinical indications for herpes simplex virus, cytomegalovirus, human immunodeficiency virus, influenza, hepatitis B virus, and hepatitis C virus drug resistance testing. Common themes include the move away from phenotypic to genotypic methods for first-line clinical testing, as well as uncertainty surrounding the clinical meaningfulness of minority variant detection as next-generation sequencing methods have become more commonplace.
Publisher
American Society for Microbiology
Reference70 articles.
1. Approved Antiviral Drugs over the Past 50 Years
2. Phenotypic and Genotypic Antiviral Susceptibility Testing
3. Huang DD, Pinsky BA, Bankowski MJ. 2019. Susceptibility test methods: viruses, p 1985–2004. In Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW (ed), Manual of clinical microbiology, 12th ed, Vol 2. ASM Press, Washington DC.
4. Antiviral Drug Resistance: Mechanisms and Clinical Implications
5. Simultaneous titration and phenotypic antiviral drug susceptibility testing for herpes simplex virus 1 and 2